The Mount Sinai conference on the pharmacotherapy of schizophrenia.
about
Effectiveness of second generation antipsychotics: a systematic review of randomized trialsNew generation antipsychotics for first episode schizophreniaSide effects of atypical antipsychotics: a brief overviewWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia.Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone.The appropriateness of routine medication treatment for schizophrenia.Incidence of tardive dyskinesia with risperidone or olanzapine in the elderly: results from a 2-year, prospective study in antipsychotic-naïve patients.The German Research Network on Schizophrenia--impact on the management of schizophreniaEfficacy of lifestyle interventions in physical health management of patients with severe mental illness.Metabolic syndrome and cardiovascular disease.Do guidelines for severe mental illness promote physical health and well-being?Weighing in: emergent diabetes mellitus and second-generation antipsychotics.Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making.Ventral tegmental area/midbrain functional connectivity and response to antipsychotic medication in schizophrenia.Risperidone Effects on Brain Dynamic Connectivity-A Prospective Resting-State fMRI Study in Schizophrenia.Prescribing pattern of clozapine and other antipsychotics for patients with first-episode psychosis: a cross-sectional survey of early intervention teams.Antipsychotic polypharmacy in schizophrenia: benefits and risks.Aripiprazole: a review of its use in the management of schizophrenia in adults.Practice regarding antipsychotic therapy: a cross-sectional survey in two Norwegian hospitals.Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial.Psychotropic prescriptions for the treatment of schizophrenia in an outpatient clinic.Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic.Tardive dyskinesia after short-term treatment with oral metoclopramide in an adolescent.Quality of life in schizophrenia on conventional versus atypical antipsychotic medication: a comparative cross-sectional study.Schizophrenia: multi-attribute utility theory approach to selection of atypical antipsychotics.Initial Clinical Experience of RP5063 Following Single Doses in Normal Healthy Volunteers and Multiple Doses in Patients with Stable Schizophrenia.Psychosis
P2860
Q21260262-1CC0130A-E397-458F-8256-83378EDE1489Q24247720-48140487-D2D8-4E94-9B4F-8B44A717590BQ24642721-52CEE900-2906-4137-9159-C92C64266658Q33223628-276A8662-1A6A-420E-A685-1706743376E4Q33235110-8DCDCDAC-260B-411E-89DB-560CE4E93436Q33545458-5537B665-E779-4CEA-A8FD-17FEE5AA306DQ33950877-5B9564E0-B85B-4B7A-B43F-3C1DB5595E0AQ34628702-FE7C3671-4A4C-460C-8B91-356FF9E8B567Q35236670-2AB464D2-51CE-488B-9F04-FAA2122E4594Q35290463-95163E89-79CC-4663-A3A8-71518EA542EAQ36310316-F32CE4C2-5FD6-4808-80F8-6E98562DD50FQ36310323-021F186F-5951-4230-A3C1-AD538502947CQ36929179-DDAE6EA7-A375-4160-BE2A-602104E81E22Q37532575-7082000D-E3F4-42D6-A8A1-EFA92FF2662BQ37584279-EC7480FE-CB06-45BA-A3CF-02A04F9F6DDEQ37625470-28F74BED-7661-4D37-AC78-E968577C6496Q37705255-5DA9BF80-C706-449E-9AAE-3469F0E465DEQ37863093-2C8029B6-FBA5-4ED7-ADB4-0AF01A1A1D6BQ37980517-E362E6C9-5F82-44DE-9211-6BC8F710501BQ45061345-33E467D5-D2B7-4090-99D5-1609C9730D10Q46069647-3108CBC9-387C-456C-90A4-D396C5CF1789Q46564630-1457AF05-7DE6-4976-9D5F-DA7FF9730D46Q46798701-B89DC6BB-1293-429C-84BA-F44AC45E032CQ48139848-1B929A2F-D2AB-473F-A8E9-1F482342673AQ51915956-FE7D8615-24BB-4457-8000-168C417CD222Q51921937-1C74AD02-BCF2-4D0B-B245-AA2698FA14D4Q53413484-39C9FA9C-BABF-4B48-9535-C9E91D000D46Q56059688-6BC0704C-15CF-49BC-BF82-8FC2FE1EF4E9
P2860
The Mount Sinai conference on the pharmacotherapy of schizophrenia.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
The Mount Sinai conference on the pharmacotherapy of schizophrenia.
@ast
The Mount Sinai conference on the pharmacotherapy of schizophrenia.
@en
The Mount Sinai conference on the pharmacotherapy of schizophrenia.
@nl
type
label
The Mount Sinai conference on the pharmacotherapy of schizophrenia.
@ast
The Mount Sinai conference on the pharmacotherapy of schizophrenia.
@en
The Mount Sinai conference on the pharmacotherapy of schizophrenia.
@nl
prefLabel
The Mount Sinai conference on the pharmacotherapy of schizophrenia.
@ast
The Mount Sinai conference on the pharmacotherapy of schizophrenia.
@en
The Mount Sinai conference on the pharmacotherapy of schizophrenia.
@nl
P2093
P1476
The Mount Sinai conference on the pharmacotherapy of schizophrenia.
@en
P2093
Alexander L Miller
John M Davis
Nina R Schooler
Robert W Buchanan
Stephen R Marder
Susan M Essock
P356
10.1093/OXFORDJOURNALS.SCHBUL.A006926
P407
P577
2002-01-01T00:00:00Z